FRISS
13.6.2019 07:02:06 CEST | Business Wire | Press release
Eurolife ERB, a Fairfax company, has won the IMPACT BITE (Business IT Excellence) Awards 2019 in the category IT Business Process Improvement, for its AI approach to assess risks and reduce the likelihood of fraud. The IMPACT Bite Awards is open to all companies, across industries, who have successfully integrated IT & tech systems and/or have taken initiatives in the domains of IT & Comms infrastructure that support their business goals. Eurolife ERB entered the competition with their successful implementation of the FRISS solution for automated fraud prevention. Thanks to this solution they lowered their loss ratio, enabled digital transformation and improved their customer experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190612005694/en/
Eurolife ERB, a leading player in the Greek insurance market, has the goal to reduce the risk it faces in cases of fraud involving future indemnities in the car insurance industry. Through the use of Artificial Intelligence, Eurolife ERB, in close cooperation with FRISS, has created a process of automated, more detailed risk assessment control, seeking faster, more complete and safer processing. This provides them with better customer service while contributing significantly to maintaining a net portfolio.
John Kostoglou, CIO of Eurolife ERB: “I’m very proud that we have won this award. It is great to see that our focus on innovation and digital transformation get recognized. For every insurance company the possibility of fraud is very high, in particular for contracts relating to the car industry. With the help of FRISS we are able to detect high risks and fraud in real-time. With this state-of-the art technology we save time and money for our customers.”
Simon Staadegaard, Sales Manager at FRISS, states: “We are delighted to see that our efforts to detect fraud and support honest insurance pay off. The recognition by IMPACT shows that the insurance industry really values the power of our AI solutions that are combined with our expert industry knowledge. The project with Eurolife ERB went smoothly. It was delivered on time and within budget. We look forward to a bright and fraud free future together.”
About Eurolife ERB
Eurolife ERB Insurance Group is a member of Fairfax Financial Holdings Ltd., who, through its subsidiaries, operates in insurances, reinsurance and investments’ management. Eurolife ERB Insurance Group, through its subsidiaries in Greece and Romania, designs, markets and promotes advanced products and services that meet the full range of contemporary insurance needs. Group companies in Greece include Eurolife ERB Life Insurance SA, Eurolife ERB General Insurance SA and ERB Insurance Brokers SA. A leading player in the bancassurance market, the Group has established a broad network of affiliated insurance agents across Greece. Group companies in Romania include Eurolife ERB Asigurari de Viata and Eurolife ERB Asigurari Generale. Eurolife ERB Insurance Group consistently maintains strong earnings levels and capital reserves in excess of European regulatory requirements, so as to always fulfil its responsibilities towards its clientele. Understanding its role in the society, Eurolife ERB Insurance Group is committed to give back to the communities a part of its profits per year. Through its corporate social responsibility program, the Group implements actions: (a) for quality of life and wellness, (b) for the promotion of education and culture, (c) for entrepreneurship and economy, supporting more choices and optimism for the future.
For more information, visit eurolife.gr
About FRISS
FRISS has a 100% focus on automated fraud and risk detection for P&C insurance companies worldwide. The AI-powered detection solutions for underwriting, claims and SIU have already helped 150+ insurers to grow their business. FRISS detects fraud, mitigates risks and supports digital transformation. Insurers go live within 6 months, with fixed price projects, and realize an ROI within 12 months. The FRISS solutions help to lower the loss ratio, enable profitable portfolio growth, and improve the customer experience. www.friss.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190612005694/en/
Contact:
Ruud van Gerwen PR & Product Marketer at FRISS +31 30 767 0352 Ruud.van.gerwen@friss.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom